Paul-Ehrlich-Institut

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Use of Mon­o­clon­al An­ti­bod­ies against COVID-19

In addition to the neutralising monoclonal antibodies Bamlanivimab (Eli Lilly) and Casirivimab/Imdevimab (Roche/Regeneron), which are already available in Germany, another monoclonal antibody from the U.S. pharmaceutical company Eli Lilly, Etesevimab, is expected to be available in Germany in June 2021 for use in combination therapy together with Bamlanivimab.

SARS-CoV-2 with antibodies (Source: Kateryna Kon/shutterstock.com)

The medicines are currently in clinical trials and have not yet been authorised. The antibody Etesevimab is to be used exclusively in combination with the antibody Bamlanivimab for the treatment of confirmed COVID-19 disease in patients aged 12 years or older, weighing at least 40 kg and who have risk factors for severe disease progression.

Bamlanivimab may continue to be used as monotherapy, taking into account the epidemiologic situation and the individual patient.

Reference is made to the current information sheets for healthcare professionals and patients on the various therapeutic options.

Updated: 31.05.2021